Hormone therapyFDA-approvedFirst-line
Bicalutamide
How it works
Blocks the action of testosterone on prostate cancer cells, preventing them from growing.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, bicalutamide has been shown to delay the progression of prostate cancer and improve survival.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Palbociclib and Bicalutamide for Metastatic Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Prostate Cancer Treatment Study | Prostate Cancer | phase-2 | — | Source → |
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | The apalutamide group showed significantly higher CRPC-free probability at 24 months (68.2% vs. 39.8%, p < 0.001) compared to the bicalutamide group. | Source → |
| Bicalutamide Treatment for Advanced Prostate Cancer | Prostate Cancer | observational | Patients at low risk for disease progression had a 5-year OS of 100% and a 10-year OS of 75%. | Source → |
| Cost-effectiveness of rezvilutamide in prostate cancer treatment | Prostate Cancer | phase-3 | The rezvilutamide group showed an expected gain of 2.28 QALYs and an incremental cost of US$60 758.82 compared with the bicalutamide group. | Source → |
| Bicalutamide-Induced Gynecomastia Reversible with Hormone Therapy | Prostate Cancer | observational | — | Source → |
| Metformin and Prostate Cancer Study Yields Mixed Results | Prostate Cancer | phase-2 | Metformin monotherapy reduced PSA levels by 4% to 24% in 40.0% of patients. | Source → |
| Apalutamide Improves Radiotherapy Effectiveness in Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Lab-Grown Tissue Model Helps Study Prostate Cancer in Bones | Prostate Cancer | lab-study | Enzalutamide presented with better treatment response, in line with enzalutamide delaying time to bone-related events and enzalutamide extending survival in mCRPC. | Source → |
| New Compounds Show Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | Compound 28 displayed significant enhancement in anticancer activity with IC = 9.09 - 31.11 µM compared to the positive controls. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.